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Abstract – The authors characterized the progress that has been 
made in the last decades in the treatment of multiple sclerosis. 
They emphasized that treatment of MS should be carried out in a 
continuous manner. As long as the patient feels the efficacy of the 
therapy or does not have any adverse effects, the treatment shall 
be continued. However, it should be remembered that while 
maintaining the individualization of therapy, not every patient 
responds to any form of therapy. They characterized groups of 
drugs selected for the specific phase of the disease. They dis-
cussed the most commonly used drugs of particular groups, they 
paid attention to the risk of developing symptoms. In many cases, 
pharmacological treatment requires support from a psychologist, 
psychiatrist, rehabilitation and physiotherapy. These last issues 
are discussed a bit more widely. 
 
Key words - multiple sclerosis, treatment. 
 
Streszczenie – Autorzy scharakteryzowali postęp jaki dokonał się 
w ostatnich dziesięcioleciach w leczeniu stwardnienia rozsianego. 
Podkreślili, że leczenie w SM należy prowadzić stale, w sposób 
ciągły. Dopóty pacjent odczuwa skuteczność terapii lub nie ma 
nasilonych, wykluczających to leczenie działań niepożądanych, 
tak długo powinien być leczony. Należy jednak pamiętać, że przy 
zachowaniu indywidualizacji terapii nie każdy chory odpowiada 
na każdą formę terapii. Scharakteryzowali grupy leków dobierane 
do fazy choroby. Omówili najczęściej stosowane leki poszczegól-
nych grup, zwrócili uwagę na ryzyko rozwoju objawów. W wielu 
wypadkach leczenia farmakologiczne wymaga wsparcia ze strony 
psychologa, psychiatry  oraz  rehabilitacji i fizjoterapii. Te ostat-
nie zagadnienia omówiono nieco szerzej.  
 
Słowa kluczowe - stwardnienie rozsiane, leczenia. 
 
Author Affiliations: 
 
1. Faculty of Health Sciences, Collegium Medicum, Jagiellonian 
University  
2. Collegium Masoviense – College of Health Sciences, Żyrar-
dów  
 
 
Authors’ contributions to the article:  
 
A. The idea and the planning of the study  
B. Gathering and listing data  
C. The data analysis and interpretation  
D. Writing the article  
E. Critical review of the article  
F. Final approval of the article  
 
Correspondence to: 
 
Prof. Zbigniew Kopański MD PhD, Faculty of Health Sciences, 
Collegium Medicum, Jagiellonian University, Piotra 
Michałowskiego 12 Str., PL- 31-126 Kraków, Poland, e-mail: 
zkopanski@o2.pl 
 
Accepted for publication: November 30, 2018. 
 
 
I. INTRODUCTION 
 
ccording to many authors, since the early 1990s, there 
has been a steady progress in the treatment of multiple 
sclerosis. The first drugs of this decade were interfer-
ons and glatiramer acetate used to treat relapsing-remitting 
disease. Currently, it is possible to use drugs that reduce the 
disease activity by as much as 60%. Nowadays, drugs from 
the group of monoclonal antibodies have been used in the 
treatment. One of them is ocrelizumab, used to treat the 
primary progressive form (a form of the disease that had 
not been treated so far). This drug is effective in relapsing-
remitting type, but as the only drug currently has a registra-
tion for the treatment of PPMS, which accounts for several 
to twenty percent of all cases of multiple sclerosis. The 
therapeutic efficacy of ocrelizumab has pointed to the un-
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noticed before role of the immune system in the develop-
ment of multiple sclerosis. 
It is emphasized that treatment in MS should be carried out 
in a continuous manner. As long as the patient feels the 
effectiveness of the therapy or does not have any severe 
side effects, this treatment should be continued for as long 
as possible [1-5]. 
 However, it should be remembered that while maintain-
ing the individualization of therapy, not every patient re-
sponds to any form of immunological therapy. Each of 
these drugs works in a different mechanism, and the es-
sence of the individual treatment is to match a patient with 
an effective drug. For 30% of patients, due to the mild 
course, effective drugs are interferons or glatiramer acetate. 
Some patients, however, require modern aggressive thera-
py. This applies mainly to the relapsing-remitting type with 
a large number of relapses at the very beginning and with a 
high risk of rapid progression of disability. [5-7] 
 A big problem in Poland is the fact that currently only 
about 26% of diagnosed patients with multiple sclerosis are 
treated, i.e. about 12,000. patients, while in the European 
Union this rate is almost twice as high and amounts to ap-
proximately 50%. In the current state of therapy in Poland, 
the most urgent task is to introduce changes in the treat-
ment of the second line. This applies to the introduction of 
new drugs as well as the extension of the therapy time. Re-
moving a patient from therapy as a result of the expiration 
of treatment in the second line may result in an increase in 
disease activity, i.e. relapses and active foci, or a rebound 
effect (after discontinuation of both one and the other linear 
drug II, a rapid increase may occur in disease activity). [8] 
 
II. TREATMENT OF MULTIPLE SCLEROSIS 
 
In the treatment of MS, four groups of drugs are used for 
the phase of the disease [1,5,8]: 
• immunomodulatory drugs – they change the natural 
course of the disease, delay its development by reducing 
the disease relapses and their severity, 
• immunosuppressive drugs – so-called emergency ther-
apy when there is a significant deterioration of health 
(their effectiveness is still being investigated), 
• symptomatic drugs – medicines adapted to a particular 
patient, prescribed by the attending physician, dedicated 
to alleviating the emerging symptoms, 
• medicines used during the attack of the disease (most 
often corticosteroids) - their task is to ‘suppress’ (immu-
nosuppression) the immune system in order to stop in-
flammatory processes. They are given to patients with re-
lapsing-remitting MS after the diagnosis. 
 Immunomodulatory treatment is recommended primarily 
in the case of relapsing-remitting disease – then the therapy 
brings the best results. The most commonly used immuno-
modulatory drugs are: beta interferons, glatiramer acetate, 
dimethyl fumarate, natalizumab, fingolimod, teriflunomide, 
alemtuzumab. [9-12] 
Immunosuppressive therapy is used in the case of severe, 
rapid relapsing-remitting MS or in a secondary progressive 
form. Mitoxantrone used intravenously is the most frequent 
in this case. The drug can give a wide range of side effects: 
nausea, hair loss, respiratory and urinary tract infections. 
[3-5] 
 Symptomatic pharmacological treatment is most com-
monly used in relation to: spasticity, dysfunction of the 
urinary tract, tiredness, pain, tremors, sexual dysfunctions, 
depression, cognitive disorders. In many cases, this type of 
treatment requires support from a psychologist, psychia-
trist, rehabilitation and physiotherapy. [5,9,12]  
 Corticosteroids are most commonly used to treat acute 
attacks. Currently, methylprednisolone is the most com-
monly used one. It is administered intravenously (in a drip 
infusion). Depending on the severity of the relapse, 
methylpredinazole is administered from 3 to 5 days. Due to 
its good efficacy, treatment with oral corticosteroids may 
also be considered. In severe relapses of the disease and 
lack of efficacy of corticotherapy, therapeutic plasmaphere-
sis (5 treatments) can be performed or intravenous immu-
noglobulins administered, especially when there are contra-
indications to conventional therapy [13-15]. 
 
III. REHABILITATION 
 
Rehabilitation is generally a process aimed at improving  
the patient's condition and, if possible, returning to the 
physical condition from before the illness. Its goal is to get 
as little disability as possible due to illness, high independ-
ence of movement, social and mental balance. Among pa-
tients with multiple sclerosis, rehabilitation is an indispen-
sable element of an effective treatment process. Patients 
with MS should be under physiotherapy at the early stages 
of the disease. Regardless of whether the diagnosis has 
already been determined or if it is probable, there are no 
obstacles to implement rehabilitation. The beginning of 
early-stage rehabilitation can prevent the patient's possible 
limitations and disabilities [16,17].  
An improvement therapy should be common, available 
and carried out regularly on a continuous basis. It cannot 
end when the patient is discharged from a medical facility, 
it is important to continue the therapy later on. Rehabilita-
tion conducted in a systematic way allows a positive influ-
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ence on the patient's mental state and general well-being. 
The course of therapy must be comprehensive, it means 
that not only the physiotherapist, but the entire rehabilita-
tion team is involved in the improvement process. It in-
cludes a physiotherapist, a main doctor, a nurse, a psy-
chologist and a social assistant. Improvement activities 
should not only take into account physical rehabilitation, 
but also mental rehabilitation, which not only will allow the 
patient to fit into the new situation, but also to accept limi-
tations and illness. Thanks to this, the patient will start to 
perceive the illness differently, which will have a positive 
impact on the whole rehabilitation process. These activities 
will be reflected in greater motivation and willingness to 
achieve more beneficial therapeutic effects [18, 19]. 
The most important goal for people with multiple sclero-
sis is to maintain their full physical and mental fitness for 
as long as possible. Other, secondary goals, include in-
creasing muscle strength and preventing its loss, eliminat-
ing contractures and maintaining the full range of joint mo-
bility, fighting spasticity, reducing the risk of balance dis-
orders and improving motor functions lost during the dis-
ease. The other tasks posed by patients also include: regula-
tion of physiological functions, combating the effects of 
immobilization, i.e. decubitus and bone decalcification, 
improvement of mental comfort, in some cases speech 
reeducation and adaptation of the patient to new living 
conditions. An inseparable element of the improvement 
process is adaptation to the activities performed daily and 
participation in social life, which changed during the course 
of illness [17,18,20,21]. 
Widely understood rehabilitation is an important element 
in the general improvement of patients. Successful therapy 
gives the opportunity to restore mobility and contributes to 
improvement in the field of social and professional rehabil-
itation. Thanks to the use of various methods and forms of 
treatment appropriately selected to the patient's condition, 
we prevent muscle atrophy, thus contributing to the in-
crease of strength, endurance and muscle mass [19]. Exer-
cises contribute to the easier flow of venous blood from the 
muscles and tissues towards the heart. This process leads to 
improved tissue trophology and increased ability of the 
muscles to work. Physical activity also significantly affects 
the maintenance of the appropriate range of movement of 
the joints as well as the flexibility and length of the muscle. 
Therapy plays a fundamental role in the functioning of the 
nervous system, where, through the selection of exercises, 
it is possible to remove coordination and balance disorders. 
Daily dose of exercises works against the negative effects 
of immobilization. An extremely important issue in the 
process of rehabilitation is to convince the patient about the 
important role that physical exercises carried out in a con-
tinuous manner play. The only exception is a discontinua-
tion of rehabilitation during exacerbation of symptoms and 
on hot days, which are often a significant hindering factor. 
Regardless of the patient's current condition, one should 
always adjust the intensity of the exercises to the endurance 
and individual capacity [17,18,21]. 
Kinesiotherapeutic methods used during treatment in-
clude PNF improvement. The PNF method is a form of 
improving the neuromuscular dysfunction, which is accom-
panied by muscle disorder. The second method used in 
therapy is the NDT Bobath concept. The main assumption 
of the mentioned method is the action aimed at renewing 
the patient's natural movement, improving impaired motor 
skills and improving the conditions for independent living. 
During the therapeutic procedure, techniques are used to 
inhibit pathologically altered movement patterns and stimu-
late physiological reactions. This action is possible with 
normalized muscle tension, i.e. one that is not pathological-
ly altered [18, 21]. 
Physical exercises are supplemented with physiothera-
peutic treatments. In the case of pain caused by the disease 
process, magnetostimulation procedures are used. One of 
the properties of magnetotherapy beneficial in multiple 
sclerosis is an increase in cerebral blood flow and stimula-
tion of peripheral nerves. Another alternative is cold treat-
ment, such as: air or carbon dioxide blowing, and ventricu-
lar systemic cryotherapy treatments. After applying the 
cooling treatments, patients should commence movement 
classes in the gymnasium. The treatments that affect the 
improvement of the patient's condition are also electrother-
apy treatments, low-frequency magnetic field, tens or 
transdermal nerve stimulation. Thermal treatments are also 
applied, to which we include irradiation with a solux lamp, 
IR laser therapy and treatments using paraffin [17, 20-22]. 
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